Tumor regression after brachytherapy for choroidal melanoma: Reduction of thickness and cross-sectional area by shape and regression pattern

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 4, 2015, Pages 2612-2623

  Rashid, Mamunur ^a   Heikkonen, Jorma ^a   Kivelä, Tero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Brachytherapy; Exponential decay; Iodine; Ruthenium; Tumor regression

Indexed keywords

RUTHENIUM 106;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; BRUCH MEMBRANE; CANCER STAGING; CHOROID MELANOMA; CONTROLLED STUDY; ECHOGRAPHY; EYE MELANOMA; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR THICKNESS; UVEA MELANOMA; ADOLESCENT; CHOROID NEOPLASMS; DISEASE COURSE; MELANOMA; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; RETROSPECTIVE STUDY; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CHOROID NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939645265     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-16322     Document Type: Article

References (53)

1. Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivela T. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003;110:2223–2234.
2. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002; 109:2197–2206.
3. Cruess AF, Augsburger JJ, Shields JA, Brady LW, Markoe AM, Day JL. Regression of posterior uveal melanomas following cobalt-60 plaque radiotherapy. Ophthalmology. 1984;91: 1716–1719.
4. Coleman DJ, Lizzi FL, Silverman RH, et al. Regression of uveal malignant melanomas following cobalt-60 plaque. Correlates between acoustic spectrum analysis and tumor regression. Retina. 1985;5:73–78.
5. Augsburger JJ, McNeary BT, von Below H, et al. Regression of posterior uveal malignant melanomas after cobalt plaque radiotherapy. Graefes Arch Clin Exp Ophthalmol. 1986;224: 397–400.
6. Augsburger JJ, Gamel JW, Shields JA, Markoe AM, Brady LW. Post-irradiation regression of choroidal melanomas as a risk factor for death from metastatic disease. Ophthalmology. 1987;94:1173–1177.
7. Abramson DH, Servodidio CA, McCormick B, Fass D, Zang E.Changes in height of choroidal melanomas after plaque therapy. Br J Ophthalmol. 1990;74:359–362.
8. Shields CL, Bianciotto C, Rudich D, Materin MA, Ganguly A, Shields JA. Regression of uveal melanoma after plaque radiotherapy and thermotherapy based on chromosome 3 status. Retina. 2008;28:1289–1295.
9. Demirci H, Saponara F, Khan A, et al. Regression rate of posterior uveal melanomas following iodine-125 plaque radiotherapy. Middle East Afr J Ophthalmol. 2015;22:103–107.
10. Houston SK, Shah NV, Decatur C, et al. Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment. Clin Ophthalmol. 2013;7:193–198.
11. Corrˆea ZM, Augsburger JJ. Relationship between rate of posterior uveal melanoma flattening following plaque radiotherapy and gene expression profile class of tumor cells. Invest Ophthalmol Vis Sci. 2014;55:556–559.
12. Lommatzsch PK. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years’ experience. Br J Ophthalmol. 1986;70:844–851.
13. Eichler C, Hertel A, Lommatzsch PK, Fuhrmann P. Echographische Befunde vor und nach beta-Bestrahlung (106Ru/106Rh) von Aderhautmelanomen. Klin Monatsbl Augenheilkd. 1987; 190:17–20.
14. Grange JD, Thacoor S, Bievelez B, et al. Etude comparative de la vitesse de r´egression tumorale de 127 m´elanomes uv´eaux irradi´es par 106 RU/106 RH. Ophtalmologie. 1990;4:221–224.
15. Guthoff R, Haase J, von Domarus D, Draeger J, Lauritzen K. Das Regressionsverhalten des Aderhautmelanoms nach Strahlentherapie– ein neuer prognostischer Parameter? Klin Monatsbl Augenheilkd. 1990;196:6–10.
16. Kaiserman I, Anteby I, Chowers I, Blumenthal EZ, Kliers I, Pe’er J. Changes in ultrasound findings in posterior uveal melanoma after Ruthenium 106 brachytherapy. Ophthalmology. 2002;109:1137–1141.
17. Georgopoulos M, Zehetmayer M, Ruhswurm I, et al. Tumour regression of uveal melanoma after ruthenium-106 brachytherapy or stereotactic radiotherapy with gamma knife or linear accelerator. Ophthalmologica. 2003;217:315–319.
18. Novak-Andrejcic K, Jancar B, Hawlina M. Echographic followup of malignant melanoma of the choroid after brachytherapy with 106Ru. Klin Monatsbl Augenheilkd. 2003;220:853–860.
19. Bartlema YM, Oosterhuis JA, Journ´ee-de Korver JG, Tjho- Heslinga RE, Keunen JE. Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years’ experience. Br J Ophthalmol. 2003;87:1370–1373.
20. Kaiserman I, Anteby I, Chowers I, Blumenthal EZ, Kliers I, Peer J. Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. Br J Ophthalmol. 2004;88:892–895.
21. Kreusel KM, Bechrakis N, Riese J, Krause L, Wachtlin J, Foerster MH. Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regres-sion and early complications. Graefes Arch Clin Exp Ophthalmol. 2006;244:1575–1580.
22. Kwon HJ, Ko JS, Kim M, Lee CS, Lee SC. Prognosis of choroidal melanoma and the result of ruthenium brachytherapy combined with transpupillary thermotherapy in Korean patients. Br J Ophthalmol. 2013;97:653–658.
23. Lee CS, Lee SC, Lee K, Kwon HJ, Yi JH, Cho A. Regression of uveal melanoma after ru-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography. Retina. 2014; 34:182–187.
24. Glynn RJ, Seddon JM, Gragoudas ES, Egan KM, Hart LJ. Evaluation of tumor regression and other prognostic factors for early and late metastasis after proton irradiation of uveal melanoma. Ophthalmology. 1989;96:1566–1573.
25. Gragoudas ES, Egan KM, Saornil MA, Walsh SM, Albert DM, Seddon JM. The time course of irradiation changes in proton beam-treated uveal melanomas. Ophthalmology. 1993;100: 1555–1559, discussion 1560.
26. Chappell MC, Char DH, Cole TB, et al. Uveal melanoma: molecular pattern, clinical features, and radiation response. Am J Ophthalmol. 2012;154:227–232, e222.
27. Mosci C, Lanza FB, Mosci S, Barla A. Quantitative echography in primary uveal melanoma treated by proton beam therapy. Can J Ophthalmol. 2014;49:60–65.
28. Mullner K, Langmann G, Pendl G, Faulborn J. Echographic findings in uveal melanomas treated with the Leksell gamma knife. Br J Ophthalmol. 1998;82:154–158.
29. Marathe OS, Wu J, Lee SP, et al. Ocular response of choroidal melanoma with monosomy 3 versus disomy 3 after iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2011;81:1046–1048.
30. Umlas J, Diener-West M, Robinson NL, Green WR, GrossniklausHE, Albert DM. Comparison of transillumination and histologic slide measurements of choroidal melanoma. Arch Ophthalmol. 1997;115:474–477.
31. Collaborative Ocular Melanoma Study Group. Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study (COMS), Report no. 12, Part I. J Ophthalmic Nurs Technol. 1999;18:143–149.
32. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst. 1999;91:523–528.
33. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
34. Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology. 2002;225:416–419.
35. Guthoff R. Modellmessungen zur Volumenbestimmung des malignen Aderhautmelanoms. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1980;214:139–146.
36. COMS Coordinating Center. Echography transmittal/worksheet. Collaborative Ocular Melanoma Study - Study Forms, May 31, 1991. Baltimore, MD: Wilmer Ophthalmological Institute; 1991:1–4.
37. COMS Coordinating Center. Procedures for standardized echography. Collaborative Ocular Melanoma Study - Manualof Procedures, January 1995. Baltimore, MD: Wilmer Ophthalmological Institute; 1995:1–21.
38. Silverman RH, Coleman DJ, Rondeau MJ, Woods SM, Lizzi FL. Measurement of ocular tumor volumes from serial, crosssectional ultrasound scans. Retina. 1993;13:69–74.
39. Li WJ, Gragoudas ES, Egan KM. Tumor basal area and metastatic death after proton beam irradiation for choroidal melanoma. Arch Ophthalmol. 2003;121:68–72.
40. Richtig E, Langmann G, Mullner K, Richtig G, Smolle J. Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas. Eye. 2004;18:619–623.
41. Gosbell AD, Barry WR, Favilla I. Computer-aided volume measurement of choroidal melanomas. Aust N Z J Ophthalmol. 1987;15:349–357.
42. Favilla I, McKenzie J, Barry W, Gosbell A, McNeil J, Ellims P. Measurement of choroidal melanomas: a comparison of methods. Aust N Z J Ophthalmol. 1988;16:59–66.
43. Gosbell AD, Barry WR, Favilla I, Burgess F. Volume measurement of intraocular tumours by cross-sectional ultrasonographic scans. Aust N Z J Ophthalmol. 1991;19:327–333.
44. Romero JM, Finger PT, Rosen RB, Iezzi R. Three-dimensional ultrasound for the measurement of choroidal melanomas. Arch Ophthalmol. 2001;119:1275–1282.
45. Salkola S, Heikkonen J, Eskelin S, Kivela T. Management ofchoroidal melanomas less than 10 mm in largest basal diameter with a 10-mm ruthenium plaque. Retina. 2014;34:2110–2120.
46. Altman DG. Practical Statistics for Medical Research. 1st ed. London: Chapman & Hall; 1991:396–402.
47. Fox J. Applied Regression Analysis, Linear Models, and Related Methods. 1st ed. Thousand Oaks: SAGE Publications; 1997:85–111.
48. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829–836.
49. Kujala E, Damato B, Coupland SE, et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol. 2013;31:2825–2831.
50. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651–4659.
51. Singh AD, Terman S, Sculley L. Estimating choroidal melanoma volume: comparison of methods. Ophthalmology. 2007;114: 1212–1214.
52. Diener-West M, Earle JD, Fine SL, et al. The COMS randomizedtrial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No. 17. Arch Ophthalmol. 2001;119:951–965.
53. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of preenucleation radiation of large choroidal melanoma I: characteristics of patients enrolled and not enrolled. COMS report no. 9. Am J Ophthalmol. 1998;125:767–778.